CN1310998A - Composite coenzyme Q10 medicine - Google Patents
Composite coenzyme Q10 medicine Download PDFInfo
- Publication number
- CN1310998A CN1310998A CN 00102763 CN00102763A CN1310998A CN 1310998 A CN1310998 A CN 1310998A CN 00102763 CN00102763 CN 00102763 CN 00102763 A CN00102763 A CN 00102763A CN 1310998 A CN1310998 A CN 1310998A
- Authority
- CN
- China
- Prior art keywords
- ubiquinone
- vitamin
- medicine
- coenzyme
- free radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 76
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 71
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940110767 coenzyme Q10 Drugs 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- 239000001301 oxygen Substances 0.000 claims abstract description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000005515 coenzyme Substances 0.000 claims abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- 229940123457 Free radical scavenger Drugs 0.000 claims abstract description 13
- 239000002516 radical scavenger Substances 0.000 claims abstract description 13
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 7
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 7
- 239000011648 beta-carotene Substances 0.000 claims abstract description 7
- 229960002747 betacarotene Drugs 0.000 claims abstract description 7
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 7
- 239000011719 vitamin A Substances 0.000 claims abstract description 7
- 229940045997 vitamin a Drugs 0.000 claims abstract description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 7
- 102000018832 Cytochromes Human genes 0.000 claims abstract description 6
- 108010052832 Cytochromes Proteins 0.000 claims abstract description 6
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 62
- 229940035936 ubiquinone Drugs 0.000 claims description 62
- 230000000694 effects Effects 0.000 description 15
- 210000003470 mitochondria Anatomy 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000035806 respiratory chain Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108010021119 Trichosanthin Proteins 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000004536 heart mitochondria Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 150000003669 ubiquinones Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000013379 Mitochondrial Proton-Translocating ATPases Human genes 0.000 description 1
- 108010026155 Mitochondrial Proton-Translocating ATPases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a complex coenzyme Q10 medicine which is composed of (wt. ratio) coenzyme 10 1, active oxygen free radical scavenger 0.1-1. Said active oxygen free radical scavenger is vitamin C, vitamin E, vitamin A, beta carotene, cytochrome C etc. Said different active oxygen free radical scavengers can be used singly or combined.
Description
The present invention relates to a kind of Coenzyme Complex Q
10Medicine is meant especially and can eliminates original ubiquinone
10The side effect to human body that preparation exists further improves the Coenzyme Complex Q of its pharmacological action
10Medicine.
Ubiquinone
10Be a member of mitochondrial respiratory chain, between complex, II and the complex III of respiratory chain, transmit electronics up and down, in the energy metabolism of synthetic ATP, play a part very important.Nineteen fifty is separated and has confirmed its chemical constitution from mitochondrion by D.Green.
Ubiquinone
10Chemical constitution
Early stage scientist is to ubiquinone
10The understanding effect that mainly is it in synthetic ATP (energy currency), just inquire into ubiquinone since the sixties from the angle medical science man who improves energy metabolism
10Clinical value.Present ubiquinone
10As the medicine listing, tablet, capsule and injection are arranged, be mainly used in the treatment that the energy metabolism that improves human body cooperates cardiovascular and cerebrovascular disease, as: ischemic heart desease, senile myocardium sclerosis, hypertensive heart disease etc.Health is under extremely tired state or suffer from chronic weak disease person and take ubiquinone
10Can improve fatigue symptom.
Scientist is to ubiquinone in recent years
10All contain ubiquinone in complex, II and the III of Its Mechanisms proof respiratory chain
10Conjugated protein (Q-binding protein).Mitochondrion in the process of synthetic ATP, ubiquinone
10Be that form with the semiquinone free radical is combined in Q
10Conjugated protein upward performance function.Once ubiquinone
10The semiquinone combined with radical less than on the albumen or when bonded albumen dissociates to get off, ubiquinone
10The semiquinone free radical will generate superoxide radical with oxygen molecule reaction.
Ubiquinone
10Physiological action mechanism:
Respiratory chain is one group of oxidase system in the cell mitochondrial, ubiquinone
10Effect be between complex, II and III, to transmit electronics, respiratory chain realizes the oxidation of biological substrate by electron transport, and the energy that the biological substrate oxidation discharges is by realizing energy currency ATP synthetic (as above the latter half of figure) with the coupled action of ATP enzyme at complex, II and IV place.As above illustrated the first half shows scientist's new discovery in recent years, and promptly the electronics of biological substrate also can pass through ubiquinone
10Spill direct and oxygen molecule reaction deleterious superoxide radical of generation and active oxygen.Ubiquinone
10The bypass reaction that electric leakage generates superoxide radical and active oxygen makes ubiquinone
10Has certain side effect, pharmacopeia record ubiquinone
10Side effect be cause erythra, stomach discomfort, loss of appetite, feel sick, diarrhoea etc.
Work as ubiquinone
10Scientist does not also recognize ubiquinone when being made into medicine
10Can generate deleterious superoxide radical by electric leakage, today, the reach of science disclosed ubiquinone
10This negative effect after, to the medicine ubiquinone
10Doing this suitable modification obviously is necessary to overcome its negative effect.
Occasion are just waiting and are finding reduced coenzyme Q before the Japan scientist
10Than common oxidized coenzyme Q
10Easilier absorbed, in order to slow down the reduced coenzyme Q of its preparation by body
10By the speed of autoxidation, he has the ubiquinone of certain reducing degree
10Added a certain amount of antioxidant in the preparation to strengthen its ubiquinone
10The stability of preparation reducing degree (patent No. 97196975.2).The multiple antioxidant that preceding occasion being are just are being recorded and narrated has ascorbic acid, tocopherol, vitamin A, beta-carotene, sodium bisulfate, sodium thiosulfate, sodium pyrosulfite and citric acid.It is to serve as antioxidant that preceding occasion are just using the purpose of vitamin C (being ascorbic acid) and E (being tocopherol), keeps reduced coenzyme Q
10The stability of reducing degree: and in its Patent right requirement also just to reduced coenzyme Q
10The qualification of ratio.Therefore how this patent is just from improving human body to ubiquinone
10Absorption consider and unresolved ubiquinone
10Electric leakage generates the bypass reaction of superoxide radical and active oxygen and makes ubiquinone
10The side effect that has.This has in essence different with the present invention.
The inventor is just at existing medicine ubiquinone
10Electric leakage generates the bypass reaction of superoxide radical and active oxygen, and makes ubiquinone
10This defective of the side effect that has through years of researches tests, and through formulated in combination many times, has been invented a kind of Coenzyme Complex Q
10Medicine.
The object of the invention provides a kind of Coenzyme Complex Q
10Medicine, it promptly keeps ubiquinone
10Drug action, reach again and overcome former ubiquinone
10The side effect of preparation.
The present invention seeks to realize like this: a kind of Coenzyme Complex Q
10Medicine is characterized in that what it was made up of the medicine of following weight ratio: ubiquinone
101, reactive oxygen free radical scavenger 0.1-1.
Described reactive oxygen free radical scavenger is vitamin C, vitamin E, vitamin A, beta-carotene, cytochrome C etc., and described various reactive oxygen free radical scavengers may be used alone, can also be used in combination.
Coenzyme Complex Q of the present invention
10One of prescription: ubiquinone
101, vitamin C 0.25;
Coenzyme Complex Q of the present invention
10Prescription two: ubiquinone
101, vitamin E 0.25;
Coenzyme Complex Q of the present invention
10Prescription three: ubiquinone
101, vitamin C 0.1: vitamin E 0.1:
Coenzyme Complex Q of the present invention
10Prescription four: ubiquinone
101, vitamin C 0.05, vitamin E 0.05, vitamin A 0.05, beta-carotene 0.05, cytochrome C 0.05.
The invention has the beneficial effects as follows: because at ubiquinone
10Add the reactive oxygen free radical scavenger in the preparation, thereby eliminated ubiquinone
10Electric leakage son generates the side effect that the bypass reaction of superoxide radical and active oxygen is brought, as erythra, stomach discomfort, loss of appetite, feel sick, diarrhoea etc.; Further improve pharmacological action, enlarged the scope of application.Zoopery: the normal feeding of mice is fed ubiquinone with adding
10With Coenzyme Complex Q
10Comparison: add and fed 5 days, feed Q every day
10Amount 2mg/100g body weight.Detect myocardial mitochondria in conjunction with Q
10Content, atpase activity and radical damage product MDA growing amount.
Zoopery is the result prove:
| Normal feeding | Add and feed ubiquinone 10 | Add Q 10And motion | Add compound Q 10And motion | |
| In conjunction with Q 10Content (umol/mg.p.) atpase activity (nmol/mg.p.) radical damage product MDA growing amount nmol/mg.p. | ?14.26±0.38 ?43.24±7.74 ?9.89±1.41 | ?18.92±1.08 ?73.73±9.33 ?19.64±2.4l | ?23.58±1.10 ?78.30±8.89 ?25.15±2.74 | ?24.34±1.22 ?83.30±8.77 ?10.22±1.32 |
Replenish ubiquinone
10(administration by gavage) can improve ubiquinone in the animal mitochondria
10In conjunction with content, ubiquinone
10With Q
10The raising of-protein-bonded combination degree helps mitochondrion greatly and makes ATP, therefore can detect significantly increasing of mitochondrial ATP synthase activity.
Last table shows: replenish ubiquinone
10After, ubiquinone in the animal cardiac muscle mitochondrion
10Can increase about 30% in conjunction with content, if replenish ubiquinone
10And carry out exercise fatigue experiment, ubiquinone in the exercise group animal mitochondria so
10Rise to 60% in conjunction with content.A large amount of ubiquinones during account for motion
10Can add in the mitochondrion and be combined in conjugated protein on, promote the synthetic of ATP, data show that atpase activity can improve about 80%.
It should be noted that additional (filling stomach) ubiquinone
10Also improved the degree that mitochondrion is subjected to oxygen free radical injury, for example mitochondria lipid is subjected to radical damage and can produces fat peroxidating product MDA.Replenish ubiquinone
10And the animal of motion can detect myocardial mitochondria MDA growing amount and increase a lot, illustrates that external source replenishes ubiquinone
10Also strengthened the degree of respiratory chain electron leak, caused the increasing of mitochondrion concentration of oxygen free radicals and cause radical damage, this is ubiquinone just
10The basic reason place of drug side effect.If replenish compound Q
10, can alleviate because the supplemented with exogenous ubiquinone owing to take in when oxygen free radical scavenger is arranged
10And the radical damage that occurs no longer increases the MDA growing amount.
Zoopery is taken compound Q in conjunction with proof
10Can keep the performance of the positive effectiveness of the synthetic ATP ability of its splicing thread plastochondria, overcome simultaneously and taken ubiquinone merely
10Caused radical damage effect.
Example 1 of the present invention:
Ubiquinone
101g, vitamin C 0.25g.
Example 2:
Ubiquinone
101g, vitamin E 0.25g.
Example 3:
Ubiquinone
101g, vitamin C 0.1g, vitamin E 0.1g.
Example 4:
Ubiquinone
101g, vitamin C 0.05g, vitamin E 0.05g, vitamin A 0.05g, beta-carotene 0.05g, cytochrome C 0.05g.
Method for making: method for making is made compound dosage forms such as tablet, capsule and injection routinely.Also can ubiquinone
10Join clothes with reactive oxygen free radical scavenger such as vitamin C, E etc. by formula proportion.By containing 10 milligrams of ubiquinones
10Metering be that unit calculates amount of formulation, encapsulated or tablet forming.Remove ubiquinone
10Other outer compositions are free radical scavenger and the general medicine filler commonly used that is added.
Claims (6)
1. Coenzyme Complex Q
10Medicine is characterized in that what it was made up of the medicine of following weight ratio: ubiquinone
101, reactive oxygen free radical scavenger 0.1-1.
2. Coenzyme Complex Q as claimed in claim 1
10Medicine is characterized in that: described reactive oxygen free radical scavenger is vitamin C, vitamin E, vitamin A, beta-carotene, cytochrome C;
Described various reactive oxygen free radical scavenger may be used alone, can also be used in combination.
3. Coenzyme Complex Q
10, it is characterized in that it is made up of the medicine of following weight ratio: ubiquinone
101, vitamin C 0.25.
4. Coenzyme Complex Q
10, it is characterized in that it is made up of the medicine of following weight ratio: ubiquinone
101, vitamin E 0.25.
5. Coenzyme Complex Q
10, it is characterized in that it is made up of the medicine of following weight ratio: ubiquinone
101, vitamin C 0.1: vitamin E 0.1.
6. Coenzyme Complex Q
10, it is characterized in that it is made up of the medicine of following weight ratio: ubiquinone
101, vitamin C 0.05, vitamin E 0.05, vitamin A 0.05, beta-carotene 0.05, cytochrome C 0.05.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00102763 CN1121856C (en) | 2000-02-28 | 2000-02-28 | Composite coenzyme Q10 medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00102763 CN1121856C (en) | 2000-02-28 | 2000-02-28 | Composite coenzyme Q10 medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1310998A true CN1310998A (en) | 2001-09-05 |
| CN1121856C CN1121856C (en) | 2003-09-24 |
Family
ID=4576546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00102763 Expired - Fee Related CN1121856C (en) | 2000-02-28 | 2000-02-28 | Composite coenzyme Q10 medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1121856C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20102100A1 (en) * | 2010-11-12 | 2012-05-13 | Scharper Therapeutics Srl | COMPOSITION FOR THE TREATMENT OF DYSFUNCTIONS OF THE SOUND SYSTEM AND OLFACTORY |
| CN104323283A (en) * | 2014-11-10 | 2015-02-04 | 厦门金达威集团股份有限公司 | Coenzyme Q10-containing nutritional composition as well as preparation method and application of coenzyme Q10-containing nutritional composition |
-
2000
- 2000-02-28 CN CN 00102763 patent/CN1121856C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20102100A1 (en) * | 2010-11-12 | 2012-05-13 | Scharper Therapeutics Srl | COMPOSITION FOR THE TREATMENT OF DYSFUNCTIONS OF THE SOUND SYSTEM AND OLFACTORY |
| WO2012063217A1 (en) * | 2010-11-12 | 2012-05-18 | Scharper Therapeutics S.R.L | Composition for treating phonatory and olfactory apparatus disorders |
| CN104323283A (en) * | 2014-11-10 | 2015-02-04 | 厦门金达威集团股份有限公司 | Coenzyme Q10-containing nutritional composition as well as preparation method and application of coenzyme Q10-containing nutritional composition |
| CN104323283B (en) * | 2014-11-10 | 2016-05-25 | 厦门金达威生物科技有限公司 | Contain alimentation composition of Co-Q10 and preparation method thereof and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1121856C (en) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1198608C (en) | Therapeutic and dietary compsns. containing essential fatty acids and bioactive disulphides | |
| KR100869444B1 (en) | Multi-layered vitamin complex tablet containing ubidecarenone | |
| CN1235542A (en) | Falty acid treatment | |
| Gordon et al. | Vitamin C in health and disease: a companion animal focus | |
| JPH06135832A (en) | Synergestic composition of medicine and preparation thereof | |
| JPH02500841A (en) | Pharmacotherapeutic uses of glutathione derivatives | |
| EP3424497A1 (en) | Pharmaceutical composition comprising myo-inositol and d-chiro-inositol | |
| JP2011144186A (en) | Composition comprising nadh/nadph | |
| CN1265560A (en) | Composition and method for curing diabetes | |
| CN101491499B (en) | Composite liposome for injection containing 12 vitamins and preparation method thereof | |
| US8642030B2 (en) | Compositions containing coenzyme Q-10 and dihydrolipoic acid | |
| DE69835824T2 (en) | ANTITUMOR COMBINATION OF 3-AMINO-1,2,4-BENZOTRIAZINE 1,4-DIOXIDE / PACLITAXEL / PLATINUM | |
| US20160081962A1 (en) | Nutritional or dietary supplements containing fatty acids and nitrite | |
| CN1121856C (en) | Composite coenzyme Q10 medicine | |
| DE10326822A1 (en) | Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids | |
| CN1127949C (en) | Composite coenzyme Q 10 health nutriment | |
| CN109481396B (en) | Fullerene aqueous solution, injection and preparation method thereof | |
| US5948823A (en) | Irradiation protection method | |
| CN1823748A (en) | Medicinal preparation of coenzyme Q10 liposome and its preparation technology | |
| CN107625127B (en) | Euphausia superba oil and ubiquinone synergistic anti-fatigue composition, capsule and preparation method | |
| CN1228057C (en) | Compound of solanesol and its preparing process | |
| CN100339074C (en) | New application of isoflavone of soybean | |
| Ostwald et al. | Effects of dietary modifications on cholesterol-induced anemia in guinea pigs | |
| CN1679914A (en) | Medicinal composition of induced glutathione and ebeselen | |
| CN1682756A (en) | Supplementing method for exogenous nitric oxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING LIXINTANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: KANG JIAN Effective date: 20100910 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100080 NO.402, UNIT 5, BUILDING 947, ZHONGGUANCUN, BEIJING TO: 100083 1804, XUEZHIXUAN BUILDING, NO.16, XUEQING ROAD, HAIDIAN DISTRICT, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100910 Address after: 100083, Beijing, Haidian District learning Road No. 16 learning Hin Building, 1804 Patentee after: Beijing calendar Biotechnology Co., Ltd. Address before: 100080 No. 947, No. 5, gate 402, Zhongguancun, Beijing Patentee before: Kang Jian |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20010905 Assignee: Outstanding Bioisystech Co., Ltd of BeiJing ZhongKe Assignor: Beijing calendar Biotechnology Co., Ltd. Contract record no.: 2015990000414 Denomination of invention: A compound coenzyme Q10 drug Granted publication date: 20030924 License type: Exclusive License Record date: 20150605 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030924 Termination date: 20160228 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |